215 related articles for article (PubMed ID: 32444454)
1. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.
Chen HY; Kuo S; Su PF; Wu JS; Ou HT
Diabetes Care; 2020 Aug; 43(8):1732-1740. PubMed ID: 32444454
[TBL] [Abstract][Full Text] [Related]
2. Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany.
Kähm K; Laxy M; Schneider U; Rogowski WH; Lhachimi SK; Holle R
Diabetes Care; 2018 May; 41(5):971-978. PubMed ID: 29348194
[TBL] [Abstract][Full Text] [Related]
3. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
O'Brien JA; Patrick AR; Caro JJ
BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
[TBL] [Abstract][Full Text] [Related]
4. Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong.
Jiao F; Wong CKH; Tang SCW; Fung CSC; Tan KCB; McGhee S; Gangwani R; Lam CLK
Diabet Med; 2017 Sep; 34(9):1276-1283. PubMed ID: 28636749
[TBL] [Abstract][Full Text] [Related]
5. Changes in prevalence of diabetic complications and associated healthcare costs during a 10-year follow-up period among a nationwide diabetic cohort.
Chen HL; Hsu WW; Hsiao FY
J Diabetes Complications; 2015; 29(4):523-8. PubMed ID: 25770886
[TBL] [Abstract][Full Text] [Related]
6. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
O'Brien JA; Patrick AR; Caro J
Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
Clarke P; Gray A; Legood R; Briggs A; Holman R
Diabet Med; 2003 Jun; 20(6):442-50. PubMed ID: 12786677
[TBL] [Abstract][Full Text] [Related]
9. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
[TBL] [Abstract][Full Text] [Related]
10. The cost of treating type 2 diabetes (CODEIRE).
Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
[TBL] [Abstract][Full Text] [Related]
11. Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: "INSIST" study.
Mohammedi K; Fauchier L; Quignot N; Khachatryan A; Banon T; Kapnang R; Kikuchi K; Ren H; Massien C; Vigié L; Larsen S; Sibon I
Cardiovasc Diabetol; 2024 May; 23(1):183. PubMed ID: 38812009
[TBL] [Abstract][Full Text] [Related]
12. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Changes in Medical Services and Related Costs in a Single Cohort of Patients Newly Diagnosed With Type 2 Diabetes, 2006 to 2012.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
Clin Ther; 2016 Jun; 38(6):1314-1326. PubMed ID: 27129399
[TBL] [Abstract][Full Text] [Related]
14. Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany.
Kähm K; Laxy M; Schneider U; Holle R
Pharmacoeconomics; 2019 Jan; 37(1):63-74. PubMed ID: 30167918
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H
Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel KR; Ali MK; Zhou X; Ng BP; Jawanda S; Proia K; Zhang X; Gregg EW; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1557-1592. PubMed ID: 33534729
[TBL] [Abstract][Full Text] [Related]
17. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
Cleveringa FG; Welsing PM; van den Donk M; Gorter KJ; Niessen LW; Rutten GE; Redekop WK
Diabetes Care; 2010 Feb; 33(2):258-63. PubMed ID: 19933991
[TBL] [Abstract][Full Text] [Related]
19. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
[TBL] [Abstract][Full Text] [Related]
20. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.
Zhuo X; Zhang P; Hoerger TJ
Am J Prev Med; 2013 Sep; 45(3):253-61. PubMed ID: 23953350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
